Michael Kane has been appointed as the Company’s new Chief Executive Officer. Dr. Vijendra Nalamothu, Tergus’ founder who has served as Chairman & CEO since 2012, will assume the role of Executive Chairman & Chief Scientific Officer.
DURHAM, N.C., Oct. 21, 2022 /PRNewswire-PRWeb/ — Tergus Pharma, a commercial scale Contract Development and Manufacturing Organization (CDMO) of semi-solid and liquid dosage forms, announced today that Michael Kane has been appointed as the Company’s new Chief Executive Officer. Dr. Vijendra Nalamothu, Tergus’ founder who has served as Chairman & CEO since 2012, will assume the role of Executive Chairman & Chief Scientific Officer.
“We are thrilled to welcome Michael Kane as the new CEO of Tergus and I am confident that he will continue the scientific excellence and transformation at Tergus. As Executive Chairman I will be able to focus more on our growth strategy and related scientific efforts, while Kane will be empowered as CEO to manage overall corporate operations. I look forward to working closely with Michael in my role as Executive Chairman & Chief Scientific Officer to help write Tergus Pharma’s next chapter,” said Dr. Nalamothu.
Mr. Kane joins Tergus with over thirty years of manufacturing experience and commercial scale operations. Prior to joining Tergus, Mr. Kane was in company leadership roles as the CEO and COO on middle market pharmaceutical and healthcare product companies that developed and manufactured topical, solid, soft gel, oral liquid and powder dosage forms across branded Rx, generic, OTC and medical nutrition segments. He was also an Operating Partner and board director at Blue Point Capital Partners, a private equity firm based in Cleveland, Ohio. Mr. Kane’s prior experience also includes operational leadership positions at Novartis and Abbott Laboratories.
Mr. Kane stated, “I am pleased to join the Tergus management team at an important inflection point in the company history. I was attracted to the role at Tergus because of their deep scientific expertise, their excellent facility, and impressive roster of clients that have developed over the past ten years. It is clear the future is very bright for the organization, and I look forward to working with employees and customers to build a leading topical CDMO.”
About Tergus Pharma
Tergus is an end-to-end contract service provider for topical pharmaceutical products supporting early phase research and formulation, drug development, testing, and both clinical and commercial manufacturing at our new 100,000 sq. ft. state-of-the-art facility in Durham, North Carolina. Tergus has developed a reputation for delivering quality results to clients for topical semi-solids and liquids for skin, otic, nasal, ophthalmic, vaginal, and rectal routes of administration. With industry-recognized leadership and expertise in method development, such as IVRT and IVPT, for topical pharmaceuticals, Tergus also provides clients with peace of mind and helps them to de-risk their product development, tech transfer, and manufacturing activities. Exclusively focused on topical development and manufacturing, Tergus brings the scientific expertise that helps our clients achieve the right balance of scientific knowhow, speed of results, and quality. For more information, please visit https://www.TergusPharma.com/
Kent Lupino, Tergus Pharma, 1 9199081575, [email protected]
SOURCE Tergus Pharma